Clinical Trial Update: Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) [Phase 3]

View source ↗

Summary

This Phase 3 trial compares pevonedistat plus azacitidine versus azacitidine alone as first-line therapy for higher-risk myelodysplastic syndromes, chronic myel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes
• Myelomonocytic Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Pevonedistat (pevonedistat)

Snippet

Sponsor: Takeda | Conditions: Myelodysplastic Syndrome, Leukemia, Myelomonocytic, Chronic | Phase 3 | Status: COMPLETED | Results posted: 2022-09-22